Treatment of Oral Semaglutide (Rybelsus) for Diabetic Patient with Past History of Crohn’s Disease

Bando H, Kawata T, Kato Y and Ogura K

Published on: 2024-04-05

Abstract

The case is a 49-year-old male with type 2 diabetes (T2D). In his past history, he suffered from Crohn’s disease (CD) in his early 20s and underwent surgery for CD, achieving complete remission after that. He was diagnosed with T2D for 7.4% of HbA1c at the health check-up in April 2022. Oral semaglutide (Rybelsus) 3 mg/day was started as glucagon-like peptide-1 receptor agonists (GLP-1 RAs). For only 4 months, HbA1c decreased to 6.2% with 4kg of weight reduction, indicating a satisfactory effect. No gastro-intestinal adverse effects (GI-AEs) were found. Previous reports showed the beneficial effects of GLP-1RAs for patients with T2D and inflammatory bowel syndrome (IBS).